好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Influence of IQ in Interpreting MMSE Scores in Patients with MS
MS and Related Diseases
P04 - (-)
115
BACKGROUND: Research has indicated that scores on the MMSE are significantly and positively related to level of cognitive sophistication, as measured by verbal IQ, even when controlling for education, and it has been suggested based on these findings that clinicians must consider verbal IQ when diagnosing neurocognitive impairment based on MMSE scores. Generalizability of the results of prior investigations is limited secondary to use of heterogeneous clinical samples with respect to diagnoses and/or comparison of scores on the MMSE to estimated IQ scores rather than true IQ scores derived from the administration of a comprehensive test of intelligence.
DESIGN/METHODS: Participants were 46 patients diagnosed with clinically definite MS by a board certified neurologist and referred for outpatient neuropsychological evaluation. Mean age and educational level of participants was 42.7 years (SD = 10.2) and 14.3 years (SD = 2.4), respectively. Mean duration of diagnosis was 8.3 years (SD = 7.5); mean Expanded Disability Status Scale was 3.8 (SD = 1.5). The sample was 98% White and 83% female. Participants were administered the MMSE and Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) as part of a more comprehensive neuropsychological evaluation.
RESULTS: Mean WAIS-IV index scores ranged from 87.7 - 94.2. Analyses revealed that MMSE scores were significantly and positively correlated with all six index scores of the WAIS-IV (r's = .65 - .80, p's < .0005). Correlations were attenuated but remained significant even when controlling for the effects of participant education (r's = .48 - .72, p's < .001).
CONCLUSIONS: 好色先生 appears to have only a modest effect on the MMSE performance of patients with MS. Clinicians must consider patient intelligence, independent of educational level, when diagnosing neurocognitive impairment based on scores on the MMSE.
Authors/Disclosures

PRESENTER 		No disclosure on file
Fred D. Lublin, MD, FAAN (Icahn School of Medicine At Mount Sinai) Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medimmune/Viela Bio/Horizon. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Receptos/Celgene/BMS. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Labcorp. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuralight. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Entelexo. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avotres. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Lublin has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Multiple entities. Dr. Lublin has stock in Avotres. Dr. Lublin has stock in Neuralight. The institution of Dr. Lublin has received research support from Brainstorm. The institution of Dr. Lublin has received research support from biogen. The institution of Dr. Lublin has received research support from NIH.